Journal
ONCOTARGET
Volume 8, Issue 9, Pages 14925-14940Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.14742
Keywords
paclitaxel; histone deacetylase inhibitor; albumin; transferrin; lipid bilayer
Categories
Funding
- National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2015R1A2A2A01004118, 2015R1A2A2A04004806]
- Medical Research Center Program through NRF - MSIP [2015R1A5A2009124]
Ask authors/readers for more resources
In this study, a transferrin-anchored albumin nanoplatform with PEGylated lipid bilayers (Tf-L-APVN) was developed for the targeted co-delivery of paclitaxel and vorinostat in solid tumors. Tf-L-APVN exhibited a sequential and controlled release profile of paclitaxel and vorinostat, with an accelerated release pattern at acidic pH. At cellular levels, Tf-L-APVN significantly enhanced the synergistic effects of paclitaxel and vorinostat on the proliferation of MCF-7, MDA-MB-231, and HepG2 cancer cells. Vorinostat could significantly enhance the cytotoxic potential of paclitaxel, induce marked cell apoptosis, alter cell cycle patterns, and inhibit the migratory capacity of cancer cells. In addition, Tf-L-APVN showed prolonged circulation in the blood and maintained an effective ratio of 1:1 (for paclitaxel and vorinostat) throughout the study period. In HepG2 tumor-bearing mice, Tf-L-APVN displayed excellent antitumor efficacy and the combination of paclitaxel and vorinostat significantly inhibited the tumor growth. Taken together, dual drug-loaded Tf receptor-targeted nanomedicine holds great potential in chemotherapy of solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available